case_images: PMC5436920_01
case_images: Initial panoramic radiograph showing a radiolucent oval image with radiopaque halo in the premolar region (arrow).
case_images: autopsy-07-01037-g01.jpg
case_images: PMC5436920_01_autopsy-07-01037-g01.jpg
case_images: g01
case_images: X-ray revealed a unilocular, oval radiolucency of 0.5 x 0.7 cm with well-defined sclerotic borders (Figure 1).
case_images: Photomicrography of the biopsy specimen showing in A and B - an infiltrative tumor composed of large cell blocks with irregular shapes and marked basophilia (H&E, 40X and 100X, respectively); C - Note that the cells had scant cytoplasm and hyperchromatic nuclei, some with crushing artifact (H&E, 400X). The immunohistochemical study showed in D positivity for cytokeratin 7 (200X).
case_images: autopsy-07-01037-g02.jpg
case_images: PMC5436920_01_autopsy-07-01037-g02.jpg
case_images: g02
case_images: The histopathologic examination revealed remarkably basophilic irregular cells with scant cytoplasm and hyperchromatic nuclei exhibiting scattered crushing artifacts (Figure 2A, 2B and 2C). The immunohistochemical study revealed positivity for citokeratin 7, chromogranin A, and TTF-1 (Figure 2D, 3A and 3B respectively) rendering the diagnosis of metastatic SCLC.
case_images: Photomicrography of the biopsy specimen showing in A positivity for chromogranin A (200X), and in B positivity for TTF-1 (200X).
case_images: autopsy-07-01037-g03.jpg
case_images: PMC5436920_01_autopsy-07-01037-g03.jpg
case_images: g03
case_images: The immunohistochemical study revealed positivity for citokeratin 7, chromogranin A, and TTF-1 (Figure 2D, 3A and 3B respectively) rendering the diagnosis of metastatic SCLC.
case_images: Panoramic radiograph 1 month after chemotherapy, showing new bone formation in the previously metastatic region.
case_images: autopsy-07-01037-g04.jpg
case_images: PMC5436920_01_autopsy-07-01037-g04.jpg
case_images: g04
case_images: After a 4-month follow-up, the patient was asymptomatic and the x-ray showed signs of bone neoformation (Figure 4).